Humacyte HUMA
NASDAQ HUMA
$0.59 +0.00 (+0.29%)
At close: Nov 11, 2026 · 4:00 PM EST

Humacyte (HUMA) Return on Equity [ROE] (2021 - 2026)

Updated

Humacyte (HUMA) reported Return on Equity [ROE] of -557.97% for Q2 2026, up 33.05 percentage points from -591.02% a year earlier and up 1100.27 percentage points from the prior quarter.

Analysis

Humacyte (HUMA) Return on Equity [ROE] (2021 - 2026) Analysis & Trends

For FY2023, Humacyte posted Return on Equity [ROE] of -155.09%, down 81.34 percentage points from FY2022.

  • By year, Return on Equity [ROE] came in at -73.75% in FY2022.
  • The Q2 2026 figure ranks as the highest quarterly Return on Equity [ROE] since Q1 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 74.39%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 19.33%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 5.63%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 21.60%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 72.13%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -31.17%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 4.66%
10 Humacyte 163.90 Mn -213.24 Mn -401,000.00 -480.56%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -480.56%
Jun 30, 2026 -516.46%
Mar 31, 2026 -1,537.39%
Jun 30, 2025 -584.21%
Mar 31, 2024 -532.54%
Dec 31, 2023 -438.38%
Sep 30, 2023 -226.18%
Jun 30, 2023 -67.25%
Mar 31, 2023 -45.48%
Sep 30, 2022 26.32%
Jun 30, 2022 22.80%
Mar 31, 2022 -23.01%
Dec 31, 2021 -26.74%
API Access

Humacyte Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=HUMA&period=max&api_key=YOUR_API_KEY